INTERVENTIONAL VASCULAR CORPORATE PRESS RELEASES

Please find below a list of our press releases.

27 Apr 2018

OPTALYSE PE Results Presented at Society for Cardiovascular Angiography and Interventions

BTG plc (LSE: BTG), the global healthcare company, highlighted the presentation of OPTALYSE PE trial results at the Society for Cardiovascular Angiography and Interventions in San Diego, California. The findings further confirm that bilateral pulmonary embolism treated in as little as 2 hours with significantly less tissue plasminogen activator (tPA) than used in previous studies1- as low as 8mg total - show significant improvement in RV/LV ratio over both the short and long term and with a very low mortality rate of 2% and an equally low recurrent PE rate of 2%.

21 Feb 2018

First Patient in Latin America Receives TheraSphere® Radioembolisation Treatment

February 28, 2018: BTG plc (LSE: BTG), a global specialist healthcare company, announced the first patient in Latin America in Mexico was treated with TheraSphere® – a treatment for hepatic neoplasia that delivers powerful radiation to tumour cells and minimizes the exposure to healthy tissue.

6 Feb 2018

OPTALYSE PE Long Term Results Reinforce Safety and Efficacy of Shorter, Lower Dose EKOS® Therapy For Pulmonary Embolism

BTG plc (LSE: BTG), the global healthcare company, today highlighted OPTALYSE PE one year trial results, presented at the International Society on Endovascular Therapy in Florida.

13 Dec 2017

Centers Commence Enrollment in KNOCOUT PE Study to Measure the Impact of Shorter, Even Safer EKOS® Therapy Protocols for Pulmonary Embolism

BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the commencement of the KNOCOUT PE study. The KNOCOUT PE study will measure how hospitals and patients are benefitting from a new standard of care in the treatment of Pulmonary Embolism utilizing EKOS® therapy with faster, and even safer protocols, proven effective in the OPTALYSE PE study.

5 Oct 2017

BTGplc acquires Roxwood Medical

London, UK, 5 October 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announces it has acquired Roxwood Medical (“Roxwood”), an innovative provider of advanced cardiovascular specialty catheters used in the treatment of patients with severe coronary and peripheral artery disease.

16 Jun 2017

ACCESS PTS Study Demonstrates Efficacy of EKOS® Therapy for Post-Thrombotic Syndrome

BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th Annual Scientific Sessions in New Orleans, June 14 to 17.

22 May 2017

OPTALYSE PE Study Demonstrates Safety and Efficacy of Shorter, Lower Dose EKOS® Therapy For Pulmonary Embolism

OPTALYSE PE Study Demonstrates Safety and Efficacy of Shorter, Lower Dose EKOS® Therapy For Pulmonary Embolism

27 Feb 2017

BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

BTG plc (LSE: BTG), the global specialist healthcare company, today announced U.S. Food and Drug Administration 510(k) clearance has been granted to the EKOS® Control Unit 4.0.

9 Jan 2017

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® system.

BTG plc (LSE: BTG), the global specialist healthcare company, today announced the first patients diagnosed with Pulmonary Embolism (PE) to be treated in Hong Kong using the newly available EKOS® system.

5 Dec 2016

PneumRx® Coils included in new global clinical guidelines and given positive recommendation to treat severe emphysema patients in France

BTG plc (LSE: BTG), the global specialist healthcare company, today announces the inclusion of treatment with PneumRx® Coils in guidelines for the management of chronic obstructive pulmonary disease (COPD) published by the Global Initiative for Chronic Obstructive Lung Disease (GOLD).